Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tak-960. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 known ✓ | P53350 | 19/20 | 0.99 |
| ▸ | BRD4 | O60885 | 2/20 | 0.78 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.78 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.62 |
| ▸ | PLK2 | Q9NYY3 | 3/20 | 0.62 |
| ▸ | RAD52 | P43351 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tak-960 SCHEMBL30237758 | 1.00 | PLK1 (0.99) | PLK1BRD4BRDTPLK3PLK2 | |
| Tak-960 SCHEMBL23277130 | 1.00 | PLK1 (0.99) | PLK1BRD4BRDTPLK3PLK2 | |
| Tak-960 SCHEMBL29361245 | 0.99 | PLK1 (1.00) | PLK1BRD4BRDTPLK3PLK2 | |
| Tak-960 SCHEMBL1560793 | 0.99 | PLK1 (1.00) | PLK1BRD4BRDTPLK3PLK2 | |
| Tak-960 SCHEMBL30047124 | 0.99 | PLK1 (1.00) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL12365359 | 0.94 | PLK1 (0.91) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL3540293 | 0.93 | PLK1 (0.88) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL12386439 | 0.93 | PLK1 (0.87) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL1560558 | 0.92 | PLK1 (0.87) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL1675852 | 0.92 | PLK1 (0.86) | PLK1BRD4BRDTPLK3PLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240264171-A1 | BIOMARKER OF HIV OR SIV INFECTED CELLS AND ITS APPLICATION | THE FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY (CN) | 2024-08-08 | — | — | US | claimed |
| EP-4379382-A1 | MARKER IN HIV AND/OR SIV-INFECTED CELL AND APPLICATION OF MARKER | The First Hospital Of China Medicial University (CN) | 2024-06-05 | — | — | EP | claimed |
| CN-116999551-A | Binding/inhibitors of PLK3 and uses thereof | 中国医科大学附属第一医院 | 2023-11-07 | — | — | CN | claimed |
| WO-2023004994-A1 | MARKER IN HIV AND/OR SIV-INFECTED CELL AND APPLICATION OF MARKER | 中国医科大学附属第一医院 | 2023-02-02 | — | — | WO | claimed |
| US-12545896-B2 | Growth inhibitor | Orizuru Therapeutics, Inc. (JP) | 2026-02-10 | — | — | US | disclosed |
| CN-114929854-B | Proliferation inhibitors | 千纸鹤治疗公司 | 2025-05-02 | — | — | CN | disclosed |
| US-12228572-B2 | Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-infected cells | THE FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY (CN) | 2025-02-18 | — | — | US | disclosed |
| US-20240264171-A1 | BIOMARKER OF HIV OR SIV INFECTED CELLS AND ITS APPLICATION | THE FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY (CN) | 2024-08-08 | — | — | US | disclosed |
| EP-4379382-A1 | MARKER IN HIV AND/OR SIV-INFECTED CELL AND APPLICATION OF MARKER | The First Hospital Of China Medicial University (CN) | 2024-06-05 | — | — | EP | disclosed |
| US-20240124846-A1 | GROWTH INHIBITOR | Orizuru Therapeutics, Inc. (JP) | 2024-04-18 | — | — | US | disclosed |
| WO-2023004994-A1 | MARKER IN HIV AND/OR SIV-INFECTED CELL AND APPLICATION OF MARKER | 中国医科大学附属第一医院 | 2023-02-02 | — | — | WO | disclosed |
| EP-4049722-A1 | PROLIFERATION INHIBITOR | Orizuru Therapeutics, Inc. (JP) | 2022-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545896-B2 | Growth inhibitor | IAPP, PLK4, IGF1R | PLK1 62/4885BRD4 2144/4885BRDT 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.